Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study by Fasola, Gianpiero et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
Drug waste minimisation and cost-containment in Medical 
Oncology: Two-year results of a feasibility study
Gianpiero Fasola*1, Marianna Aita1, Luisa Marini1, Alessandro Follador1, 
Marina Tosolini2, Laura Mattioni2, Mauro Mansutti1, Andrea Piga1, 
Silvio Brusaferro3 and Giuseppe Aprile1
Address: 1Department of Medical Oncology, University Hospital of Udine, 33100 Udine, Italy, 2Unit of Pharmacy, University Hospital of Udine, 
33100 Udine, Italy and 3Department of Experimental and Clinical Pathology and Medicine, University Hospital of Udine, 33100 Udine, Italy
Email: Gianpiero Fasola* - fasola.gianpiero@aoud.sanita.fvg.it; Marianna Aita - aita.marianna@aoud.sanita.fvg.it; 
Luisa Marini - unblast@aoud.sanita.fvg.it; Alessandro Follador - follador.alessandro@aoud.sanita.fvg.it; 
Marina Tosolini - tosolini.marina@aoud.sanita.fvg.it; Laura Mattioni - mattioni.laura@aoud.sanita.fvg.it; 
Mauro Mansutti - mansutti.mauro@aoud.sanita.fvg.it; Andrea Piga - piga.andrea@aoud.sanita.fvg.it; 
Silvio Brusaferro - brusaferro.silvio@aoud.sanita.fvg.it; Giuseppe Aprile - aprile.giuseppe@aoud.sanita.fvg.it
* Corresponding author    
Abstract
Background:  Cost-containment strategies are required to face the challenge of rising drug
expenditures in Oncology. Drug wastage leads to economic loss, but little is known about the size
of the problem in this field.
Methods: Starting January 2005 we introduced a day-to-day monitoring of drug wastage and an
accurate assessment of its costs. An internal protocol for waste minimisation was developed,
consisting of four corrective measures: 1. A rational, per pathology distribution of chemotherapy
sessions over the week. 2. The use of multi-dose vials. 3. A reasonable rounding of drug dosages.
4. The selection of the most convenient vial size, depending on drug unit pricing.
Results: Baseline analysis focused on 29 drugs over one year. Considering their unit price and
waste amount, a major impact on expense was found to be attributable to six drugs: cetuximab,
docetaxel, gemcitabine, oxaliplatin, pemetrexed and trastuzumab. The economic loss due to their
waste equaled 4.8% of the annual drug expenditure. After the study protocol was started, the
expense due to unused drugs showed a meaningful 45% reduction throughout 2006.
Conclusion: Our experience confirms the economic relevance of waste minimisation and may
represent a feasible model in addressing this issue.
A centralised unit of drug processing, the availability of a computerised physician order entry 
system and an active involvement of the staff play a key role in allowing waste reduction and a 
consequent, substantial cost-saving.
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Background
The past ten years have seen a significant and progressive
cost rising in Medical Oncology [1], largely due to the
increase in cancer prevalence and the incorporation into
clinical practice of novel, highly expensive drugs [2].
Indeed, the formidable bounce of recent scientific
progress has led to the development, approval and licens-
ing of novel, both cytotoxic and biological agents; these
drugs have shown efficacy in clinical trials, provide further
hope to cancer patients but are among the costliest in
medical care [1].
The cost of one cycle of chemotherapy may range from
2,500 $ for docetaxel 75 mg/m2 to 4,000 $ for peme-
trexed 500 mg/m2, both delivered every three weeks [3].
As for biological agents, one month of treatment costs
from 2,300 $ for erlotinib to more than 4,000 $ for both
trastumuzab and bevacizumab [1,4]. Even more expen-
sive is cetuximab, that sells for 8,700 $ monthly [1].
Ims Health, provider of consulting services for pharma-
ceutical and healthcare industries, anticipates that by
2008 antineoplastic drugs will become the top therapeutic
area and their market will total over 40 billions USD, an
almost 50% increase as compared with 2004 [5].
Thus, the "oncologic time bomb" predicted in 1999 by an
American Cancer Society task force has exploded [2] and
the question of how patients and society will afford dra-
matically rising drug payments remains partly unan-
swered.
Several strategies have been suggested to this end: from
the promotion of an evidence-based medicine to the
adoption of validated endpoints both in clinical studies
and in the process of drug approval [6]; from the search of
relevant biomarkers for a better identification of respon-
sive patients [7] to a proper allocation of health systems
resources toward the fields of disease prevention and early
detection [8]. Overall, it seems that comprehensive
actions resulting from a thoughtful debate among the
oncological community, the government, pharmaceutical
industries and health insurers are needed to secure the
financial future of health systems. Nonetheless, the for-
mulation of satellite measures, short-run but also zero-
cost may be highly desirable in such a scenario.
Drug waste may be defined as the consequence of an inap-
propriate disposal of unused or partially used ampoules,
vials, or syringes of drugs [9]. It has been previously dem-
onstrated that inefficiency of drug use and waste produc-
tion may lead to a distinct economic loss, though
experiences are limited and most studies are dated or
focus on other therapeutic areas [9-12]. Decreasing waste
is an attractive cost-cutting strategy since it neither limits
specific drug use nor affects quality of care.
Our Department of Medical Oncology is a research-ori-
ented academic unit, admitting about two thousands new
patients every year. Facilities include an eighteen-bed day-
hospital service and a fourteen-bed ward. The Clinic hosts
a centralised unit for drug preparation and is equipped
with a homegrown computerised physician order entry
(CPOE) system; these features offer a unique opportunity
for a sound management of drug preparation, prescrip-
tion and administration.
In this framework, a project of drug use surveillance and
waste reduction was designed and launched at the end of
2004. The project aimed at:
- monitoring the global amount of CT waste during a one-
year observation period
- estimating the resulting economic loss and the relative
influence of each drug
- measuring the cost-saving effect of a number of pro-
posed corrective measures. More specifically, a per pathol-
ogy/per drug organisation of treatment sessions over the
week – in order to allow the re-use of leftovers while
respecting drug stability – as well as a reasonable round-
ing of drug dosages (i.e., within 5% of calculated dose)
[13] were encouraged. Multi-dose vials, that maintain
much longer microbial and chemical stability, were used
whenever possible, and – depending on drug unit pricing
– the most convenient vial sizes were selected for use
among available options.
Here we report on first two-year results.
Methods
2005: observation phase
Since January 2005, the number of dilution cycles for the
whole Hospital and for each Department was recorded
monthly. Four dedicated laboratory technicians started a
day-to-day monitoring of 29 prescription drug order
forms, actual use and resulting waste. More specifically, a
daily log was manually filled in by individual staff compo-
nents of the cytotoxic reconstitution unit, who analysed
the total amount of each drug prescription and the real
amount of consumed drugs, and computed the difference.
The Hospital Pharmacy provided a periodical report on
the negotiated price per milligram of each observed drug,
so that planned and de facto expense could be compared
and the economic loss due to waste exactly determined.
Monthly variations in the waste of each drug and possible
reasons were recorded. A Web literature search was per-BMC Health Services Research 2008, 8:70 http://www.biomedcentral.com/1472-6963/8/70
Page 3 of 8
(page number not for citation purposes)
formed and different domestic and international realities
analysed for matching experiences.
Finally, an internal protocol for waste minimisation could
be developed, consisting of four major corrective meas-
ures:
- a rational, per pathology/per drug distribution of chemo-
therapy sessions over the week, in order to allow the re-
use of leftovers in other patients on the same or the fol-
lowing day, while respecting both chemical and microbio-
logical drug stability. In particular, a model of
organisation was devised and launched, scheduling the
CT sessions for gastrointestinal malignancies to take place
on Monday and Wednesday, those for thoracic malignan-
cies on Tuesday, and breast cancer treatment sessions on
Thursday and Friday
- the choice, whenever possible, of multi-dose vials, that
maintain microbial and chemical stability for up to 28
days
- a reasonable rounding of drug dosages (i.e., within 5%
of calculated dose) [13], to fit with available vial sizes/left-
overs and avoid the waste of unstable medications
- the selection of the most convenient vial size among dif-
ferent available options, depending on drug unit pricing
and on an accurate estimate of the daily actual need of
each drug, based on the analysis of validated CPOE pre-
scriptions
2006, first semester
Starting January 2006, the protocol of waste reduction
was shared with all staff members and formally adopted.
Monthly dilutions, as well as every-day drug prescription
and actual consumption continued to be strictly recorded.
Possible variations in drug unit pricing were documented.
Drug recovery and resulting money saving were registered
monthly for each observed drug. Drug waste cost for the
whole year was estimated on the basis of first semester's
results and compared with 2005 expenses due to leftovers.
Both figures were put in proportion and compared with
effective 2005 and estimated 2006 total drug expenditures
of the Department, respectively.
A final report was prepared at the end of this period and
distributed to all members of the medical staff.
2006, last semester
Starting July 2006, the Authors decided to focus waste
minimisation policies and economic analysis on the six
drugs that – on the basis of 2005 observations and 2006
first semester's results – appeared to play a primary role
from a cost-cutting perspective. In particular, cetuximab,
docetaxel, gemcitabine, oxaliplatin, pemetrexed and tras-
tuzumab were selected for analysis. Despite a relatively
low drug waste cost during 2005, cetuximab was chosen
for two reasons: first, its use was predicted to greatly
increase during the following years, as a consequence of
marketing approval in Italy in July 2005; second, it was
one of the drugs for which a rational allotment of treat-
ment sessions was expected to produce the maximum
effect. Although its waste proportion and waste cost were
relatively high, topotecan was excluded from further anal-
ysis since its occasional use made it a poor candidate for
waste recovery. In the same way paclitaxel was not
included among "hot drugs", since the introduction of
multidose vials from the beginning of the year had
allowed to avoid any further drug loss.
In October 2006, an effort was made to improve the prac-
tice of dose rounding; indeed, all staff members were pro-
vided with a leaflet indicating the most reasonable dose
rounding depending on body surface/weight and availa-
ble vial sizes. Analogous brochures were made available
in all Day Hospital offices.
Projected waste cost of the six hot drugs for the whole year
and its proportion relative to the overall pharmaceutical
expenditure were calculated and compared with both
2005 findings and the initial results (i.e. those of first
semester) of waste-containment policies. Finally, 2006
figures were taken all together and compared directly to
2005 observations.
A decrease in negotiated drug prices occurred in this
period was taken into account when comparing waste
costs of the first vs the last six months of the year; in par-
ticular, all estimates were repeated as if prices didn't show
any variation. For the same reason, an average price per




Monthly mean dilutions were 1,102 for the whole Hospi-
tal, 633 for the Oncology Unit only.
Waste proportion for all 29 drugs equaled 9.6% of the
total amount of reconstituted drugs, with a net loss of
180,000 €, corresponding to 6.4 per cent of the Depart-
ment's annual drug expenditures (Table 1).
Fluctuations in waste proportion appeared to be of differ-
ent magnitude for different drugs, and median wastage
rate showed marked variability as well, ranging from 1.1%
for bleomycin to more than 50% for topotecan.BMC Health Services Research 2008, 8:70 http://www.biomedcentral.com/1472-6963/8/70
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Waste cost of six compounds only, namely cetuximab,
docetaxel, gemcitabine, oxaliplatin, pemetrexed and tras-
tuzumab, accounted for 74% (= 133,292 €) of the total
cost of wastes (Table 1) and 4.8 per cent of the Depart-
ment's annual expenditures (Figure 1). On the other
hand, their waste amount was 14% only of all the waste
and their annual wastage rate was generally lower than
10%, with the only exception of pemetrexed and trastuzu-
mab (wastage rate 14.6% and 18%, respectively).
2006, first semester
Median number of monthly dilutions was consistent with
2005 figures: 1,006 for the whole Hospital, 621 for the
Oncology Department. Notably, no variation occurred in
drug pricing nor in staff cost.
Following the application of waste containment meas-
ures, waste proportion for all drugs decreased from 9.6 to
6.5%, meaning a 41 per cent reduction of the overall
waste cost as compared to the previous year and a decrease
from 6.4 to 3.1% with respect to the estimated pharma-
ceutical expenditure (Table 2).
Corrective measures were successful in reducing the waste
proportion of all "hot" drugs, with the only exception of
docetaxel, whose leftovers did not show any substantial
variation. In particular drug waste for gemcitabine, oxali-
platin and trastuzumab dropped from 5.5 to 2%, 6.7 to
4% and 17.9 to 7%, respectively (Figure 2).
The cost of wastage of the six "hot" compounds decreased
from 4.8 to 2.5% of the overall pharmaceutical expendi-
ture (Figure 1). Indeed, the projected cost of their leftovers
for the whole year was estimated to be 85,166 € – as com-
pared to 133,292 € in 2005, meaning a planned saving of
about 50,000 €.
2006, last semester
The last semester of 2006 did not show any substantial
variation in drug preparation time and in staff monthly
workload: median number of dilutions was 1,159 for the
whole Hospital, 710 for the Oncology Unit only. Staff cost
was the same as the previous six months.
Starting July, 2006, waste minimisation policies and eco-
nomic analysis were focused on the six drugs listed in the
Methods section. By year's end, the positive trend in waste
Table 1: 2005 baseline evaluation of drug request, drug consuming, waste proportion and correspondent cost








Cost of consumed 
drugs (€)
Drug waste cost 
(€) 
Bleomycin 1735 1755 1.1 1.19 2088 24
Carboplatin 115367 123380 6.5 0.082 10117 657
Cetuximab 23110 24000 3.7 2.079 49896 1850
Cyclophosphamide 834568 943265 11.5 0.005 4716 543
Cisplatin 76300 83094 8.2 0.172 14292 1169
Dacarbazine 8310 10100 17.7 0.023 232 41
Docetaxel 31957 33640 5.0 7.525 253141 12665
Doxorubicin 24980 26380 5.3 1.46 38515 2044
Liposomial 
Doxorubicin
1406 1500 6.3 17.69 26535 1663
Epirubicin 64765 67160 3.6 1.907 128074 4567
Etoposide 63176 72300 12.6 0.022 1591 201
5-fluorouracil 5149000 5769000 10.7 0.002 11538 1240
Fotemustine 1653 2288 27.8 2.15 4919 1365
Gemcitabine 1692015 1790600 5.5 0.142 254265 13999
Iphosphamide 43150 52000 17.0 0.014 728 124
Irinotecan 95629 97690 2.1 1.76 171934 3627
Methotrexate 23531 26690 11.8 0.055 1468 174
Mitomycin 273 470 41.9 2.06 968 406
Mitoxantrone 134 150 10.7 5.39 808 86
Oxaliplatin 84095 90050 6.7 3.71 334085 22093
Paclitaxel 120948 126502 4.4 2.376 300569 13196
Pemetrexed 36290 42500 14.6 2.54 107950 15773
Raltitrexed 36 42 14.3 62.5 2625 375
Topotecan 192 392 51.1 64.72 25370 12944
Trastuzumab 65003 79270 17.9 4.69 371776 66912
Vinblastine 169 240 29.6 0.991 238 70
Vincristine 62 71 12.7 2.09 148 19
Vindesine 3 5 40.0 20.78 104 42
Vinorelbine 13659 14530 5.9 1.96 28479 1707
TOTAL 8571516 9479064 9.6 2147169 179576
a2006 official hospital drug prices in Italy are available at [21]BMC Health Services Research 2008, 8:70 http://www.biomedcentral.com/1472-6963/8/70
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reduction was confirmed, with regard especially to the
wastage of gemcitabine, docetaxel, oxaliplatin and trastu-
zumab, that showed a 75 (from 2 to 0.5%), 72 (from 5.3
to 1.5), 55 (from 4 to 1.8%) and 50 (from 7 to 3.5%) per
cent further drop, as compared to the first six months (Fig-
ure 2). The decrease in the waste rate of pemetrexed was
less important, from 13.3 to 12%, while cetuximab
inverted its trend, with an increase in wastage rate from
2.8 to 4.9%. Nonetheless the overall projected waste cost
further abated from 85,166 to 62,952 € (Figure 1), mean-
ing a 26% absolute reduction and a 28% reduction of its
fraction relative to the pharmaceutical global expenditure,
from 2.5 to 1.8% (Figure 1).
The decrease in negotiated drug prices occurred in this
period ranged from a minimum of 3% for trastuzumab to
a maximum of 10% for pemetrexed. When repeating all
estimates as if prices had not shown any variation (Table
3) we found that drug waste cost for cetixumab, docetaxel,
gencitabine, pemetrexed and trastuzumab would have
grown of 112, 94, 56, 1,130 and 364 euros, respectively,
whereas that of oxaliplatin would have decreased, from
3,329 to 3,302 €. Overall, the waste cost of the six drugs
would have raised of 1,729 € only, meaning a 24%
decrease of its fraction of the overall drug expense, from
2.5 to 1.9%.
Discussion
In days when mankind's knowledge of cancer is greater
than ever before [14] and the number and cost of new
anticancer drugs are rising to unexpected heights, over-
coming the disproportion between health needs and
available resources represents a moral as well as an eco-
nomic challenge [15].
Unfortunately, most of the strategies that have been pro-
posed to escape the need for health care rationing [16]
represent medium-long term solutions, whose impact on
high and rising costs is expected to be appreciable in a
hardly predictable future. Prompter suggestions are prob-
ably needed to control the problem in a short term-ori-
ented manner.
In this perspective, our experience shows how a relatively
simple policy of drug waste reduction may significantly
decrease their cost impact on the overall pharmaceutical
expenditure and allow a substantial cost-saving.
In 2005 a net loss of 180,000 €, corresponding to 6.4 per
cent of the Department's annual expenditures (i.e.
2,800,000 €), could be attributed to futile drug leftovers.
Waste cost of six high-priced and/or widely used drugs, i.e.
cetuximab, docetaxel, gemcitabine, oxaliplatin, peme-
trexed and trastuzumab, accounted for three-quarters of
this loss and to 4.8 per cent of the Department's annual
Waste cost proportion of "hot" drugs: 2005 vs 2006, first and second semester Figure 1
Waste cost proportion of "hot" drugs: 2005 vs 2006, first and second semester.BMC Health Services Research 2008, 8:70 http://www.biomedcentral.com/1472-6963/8/70
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drug expenditures. A strict monitoring of drug use
endorsed to acknowledge: first, that recovery policies
would probably not apply to drugs showing minor fluctu-
ations in monthly wastage rates, since low variability
implied the existence of a somehow physiologic, thus
unrecoverable, loss; second, that main reasons for drug
waste were essentially the limited extent of CT medication
shelf-life and the narrow availability of a range of vial
sizes flexibly matching with possible drug dosages.
Adopted corrective measures were the logical conse-
quence of these findings: if drug instability is a basis for
drug waste, it is reasonable to use, whenever possible,
multi-dose vials, that retain a much longer microbial and
chemical stability; and to operate a per pathology/per
drug distribution system of chemotherapy sessions over
the week, in order to allow the re-use of leftovers in other
patients, while respecting drug stability. In the same way,
if market available vial sizes are relatively few, it makes
sense to round down the drug dose to the closest accessi-
ble vial size. Notably, dose-rounding has been considered
acceptable to within 5% of calculated dose, since on the
basis of pharmacokinetic and clinical issues this dose
adjustment is not expected to have any significant effect
on either response or toxicity [13,17-19].
In our work we show how the application of straightfor-
ward measures allowed to abate the waste amount of the
most expensive antineoplastic drugs, its cost and its pro-
portion of total drug expenditure. In particular, a direct
comparison of 2005 figures with 2006 reveals how the
overall waste amount for the six "hot" dugs dropped of
66%, its cost decreased of 45% (from 133,292 € to 73,975
€, using an average price per milligram) and its fraction of
pharmaceutical global expenditure diminished from 4.8
to 2.2%.
Further expenditure cuts may hopefully emerge from
other equally feasible solutions. The establishment of an
ad hoc policy for recovering unused, unexpired oral anti-
neoplastic drugs (including biological agents) would
allow a considerable medication return and money-sav-
ing. A concrete cooperation with manufacturing compa-
nies should be solicited focusing on ways to improve and
validate the stability of drugs, particularly those items that
need to be used within hours, and on the production of
more suitable final dosage forms (for example, the
decrease in pemetrexed wastage rate was less important
than for the other hot drugs, since the possibility of drug
recovery suffered from the limits imposed by commer-
cially available vial sizes).
Table 2: 2006, first semester results








Cost of consumed 
drugs (€)
Drug waste cost 
(€)
Bleomycin 000 1 . 1 9 00
Carboplatin 62975 63185 0.3 0.082 5181 17
Cetuximab 47940 49300 2.8 2.079 102495 2827
Cyclophosphamide 334314 356500 6.2 0.005 1782 111
Cisplatin 40664 42190 3.6 0.172 7257 262
Dacarbazine 42730 45700 6.5 0.023 1051 68
Docetaxel 15630 16500 5.3 7.525 124162 6547
Doxorubicin 11532 11880 3 1.46 17345 508
Liposomial 
Doxorubicin.
960 1090 12 17.69 19282 2300
Epirubicin 31350 31580 0.7 1.907 60223 439
Etoposide 11855 14200 16.5 0.022 312 52
5-fluorouracil 2769077 3019370 8.3 0.002 6039 501
Fotemustine 1000 1040 3.8 2.15 2236 86
Gemcitabine 786330 802000 2 0.142 113884 2225
Iphosphamide 132050 137000 3.6 0.014 1918 69
Irinotecan 47995 48695 1.4 1.76 85703 1232
Methotrexate 9118 9700 6 0.055 533 32
Mitomycin 196.5 250 21.4 2.06 515 110
Mitoxantrone 15 20 25 5.39 108 27
Oxaliplatin 47033 49000 4 3.71 181790 7298
Paclitaxel 43932 43932 0 2.376 104382 0
Pemetrexed 26020 30000 13.3 2.54 76200 10109
Raltitrexed 37 42 11.9 62.5 2625 312
Topotecan 114 168 32.2 64.72 10873 3495
Trastuzumab 38433 41328 7 4.69 193828 13577
Vinblastine 25 20 25 0.991 20 5
Vincristine 20 22 9 2.09 46 4
Vindesine 50.5 65 22.3 20.78 1351 301
Vinorelbine 6718 6785 0.9 1.96 13299 131
TOTAL 4508114 4821562 6.5 1134440 52645
a2006 official hospital drug prices in Italy are available at [21]BMC Health Services Research 2008, 8:70 http://www.biomedcentral.com/1472-6963/8/70
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Our study has some limitations. First, it was conducted at
a single centre and its generalisability to settings of differ-
ent size and with a potentially different mix of diagnoses
and disease severity needs to be confirmed.
Second, the rigorous planning of chemotherapy sessions
across the week – which plays a key role in waste contain-
ment – requires a strictly organised structure and such a
policy may be difficult to pursue, especially in the absence
of a clinical information system. The increase in cetuxi-
mab wastage rate during the second semester of 2006,
which was probably due to a demanding 24-hour concen-
tration of chemotherapy sessions for colorectal cancer
patients, is an example of such a hindrance. At present, we
are working toward the validation and inward testing of
drug microbial stability, with the aim of easing the plan-
ning and escaping from the needs of a too rigid system.
Finally, it has been previously estimated that potential
savings from the reduction of inefficiencies fall short of
Table 3: 2006, second semester results












Drug waste cost 
(€)
Drug waste cost 
according to 1st 
semester's prices 
(€)
Cetuximab 31483 33100 4.9 2.01 66531 3250 3362
Docetaxel 20491 20811 1.5 7.23 150463 2314 2408
Gemcitabine 1132387 1138600 0.5 0.133 151434 826 882
Oxaliplatin 49370 50260 1.8 3.74 187972 3329 3302
Pemetrexed 31656 36000 12 2.28 82080 9904 11034
Trastuzumab 71345 73950 3.5 4.55 336472 11853 12217
TOTAL 1336732 1352721 1.2 974952 31476 33205
a2006 official hospital drug prices in Italy are available at [21]
"Hot" drug decrease in waste proportion: 2005 vs 2006, first and second semester Figure 2
"Hot" drug decrease in waste proportion: 2005 vs 2006, first and second semester.BMC Health Services Research 2008, 8:70 http://www.biomedcentral.com/1472-6963/8/70
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administration's cost containment [20]; thus, our strategy
may best function as an interim measure, in hold of more
comprehensive, long-term plans to achieve sustainable
outcomes.
Conclusion
Our study demonstrates that in Medical Oncology drug
waste reduction is feasible and economically convenient.
The existence of a centralised unit for drug manufacturing,
providing a continuous surveillance on drug prescription
and utilisation, a meticulous planning of daily workload,
granted by CPOE, and an actively shared information and
feedback among staff members are key elements to suc-
cessfully pursue the proposed strategies.
The concept of "sustainability" should not allude only to
the mandate of reducing health care expenditure. A sus-
tainable oncology is economically affordable; at the same
time it provides to all the community an equal right to
proper levels of physical and mental well-being and aims
to ceaseless progress and innovation. In this sense, the
identification of easily applicable solutions, that allow to
control rising costs while maintaining or improving the
quality of patient care, remains challenging but highly
attractive.
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